Tscan Cash Per Share from 2010 to 2024

TCRX Stock  USD 4.52  0.26  6.10%   
Tscan Therapeutics Cash Per Share yearly trend continues to be fairly stable with very little volatility. Cash Per Share will likely drop to 2.84 in 2024. During the period from 2010 to 2024, Tscan Therapeutics Cash Per Share regression line of annual values had r-squared of  0.30 and arithmetic mean of  2.38. View All Fundamentals
 
Cash Per Share  
First Reported
2010-12-31
Previous Quarter
2.92750634
Current Value
2.84
Quarterly Volatility
1.52083376
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Tscan Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tscan Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 2.5 M, Interest Income of 6.6 M or Depreciation And Amortization of 3.4 M, as well as many indicators such as Price To Sales Ratio of 17.26, Dividend Yield of 0.0 or PTB Ratio of 2.66. Tscan financial statements analysis is a perfect complement when working with Tscan Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Tscan Therapeutics Correlation against competitors.
For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.

Latest Tscan Therapeutics' Cash Per Share Growth Pattern

Below is the plot of the Cash Per Share of Tscan Therapeutics over the last few years. It is Tscan Therapeutics' Cash Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tscan Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 5.22 X10 Years Trend
Slightly volatile
   Cash Per Share   
       Timeline  

Tscan Cash Per Share Regression Statistics

Arithmetic Mean2.38
Geometric Mean2.10
Coefficient Of Variation63.99
Mean Deviation1.07
Median1.67
Standard Deviation1.52
Sample Variance2.31
Range5.3561
R-Value0.54
Mean Square Error1.76
R-Squared0.30
Significance0.04
Slope0.18
Total Sum of Squares32.38

Tscan Cash Per Share History

2024 2.84
2023 2.93
2022 4.99
2021 6.75
2020 1.4

About Tscan Therapeutics Financial Statements

Tscan Therapeutics investors use historical fundamental indicators, such as Tscan Therapeutics' Cash Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Tscan Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash Per Share 2.93  2.84 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Tscan Stock Analysis

When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.